Cancer research communications最新文献

{"title":"The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models.","authors":"Nathan M Jameson, Daehwan Kim, Catherine Lee, Blake Skrable, Alexandra Shea, Xiao Guo, Hooman Izadi, Mona Abed, Olivier Harismendy, Jianhui Ma, Doris S Kim, Mark R Lackner","doi":"10.1158/2767-9764.CRC-24-0411","DOIUrl":"10.1158/2767-9764.CRC-24-0411","url":null,"abstract":"<p><strong>Significance: </strong>Resistance to KRASG12C inhibitors is a growing clinical concern. The synergistic interaction observed between azenosertib and multiple KRASG12C inhibitors could result in deeper and more durable responses.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"240-252"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11795354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study.","authors":"William C Reinhold, Elisabetta Marangoni, Fathi Elloumi, Remi Montagne, Sudhir Varma, Yanghsin Wang, Keyvan Rezai, Ludivine Morriset, Ahmed Dahmani, Rania El Botty, Léa Huguet, Makito Mizunuma, Naoko Takebe, Samuel Huguet, Augustin Luna, Yves Pommier","doi":"10.1158/2767-9764.CRC-24-0435","DOIUrl":"10.1158/2767-9764.CRC-24-0435","url":null,"abstract":"<p><strong>Significance: </strong>Acetalax and bisacodyl represent a prospective novel drug mechanism-of-action type, affect mitochondrial function and affect tumor growth in vivo. Their activity may be predicted by TRPM4 but with more accuracy adding other genes in multivariate analysis for triple negative breast cancer (TNBC). Acetalax has a biphasic mean half-life of 5.8 hours.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"375-388"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age at First Full-term Pregnancy and Other Reproductive Factors Are Associated with Mammographic Breast Density in Postmenopausal Women: A Study in Flanders, Belgium.","authors":"Magda J Vandeloo, Eliane Kellen, Carolyn Y Fang, Eric A Ross, Liesbeth Vancoillie, Liesbeth M Bruckers, Kristof Y Neven, Esmée M Bijnens, Tim S Nawrot, Chantal Van Ongeval","doi":"10.1158/2767-9764.CRC-24-0561","DOIUrl":"10.1158/2767-9764.CRC-24-0561","url":null,"abstract":"<p><strong>Significance: </strong>We consider our findings to be highly novel, and to the best of our knowledge, our study is one of the first to investigate associations between age at FFTP and three markers of MBD (GLAND, VBD, and BI-RADS), uncovering that MBD is significantly higher when FFTP occurs after 25.7 years.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"267-276"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11803437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Incidence of Anaplastic Lymphoma Kinase Alterations in Hispanics with Non-Small Cell Lung Cancer at a Large Academic Institution in Los Angeles.","authors":"Darin Poei, Sana Ali, Jacob S Thomas, Jorge J Nieva, Robert C Hsu","doi":"10.1158/2767-9764.CRC-24-0504","DOIUrl":"10.1158/2767-9764.CRC-24-0504","url":null,"abstract":"<p><strong>Significance: </strong>This study identified a higher incidence of ALK alterations in Hispanic patients with NSCLC (12.76%) compared with that in non-Hispanic patients (5.36%) treated at a large academic center in Los Angeles, highlighting the impact of race on molecular alteration profiles and emphasizing the need to increase access to molecular analyses for this population. The variability in mutational alterations may be influenced by biological and environmental factors.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"277-286"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11808653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting.","authors":"John R Lozada, Andrew Elliott, Mark G Evans, James Wacker, Kathleen M Storey, Emily A Egusa, Nicholas A Zorko, Akhilesh Kumar, Anthony Crymes, Elisabeth I Heath, Benedito A Carneiro, Heloisa P Soares, Frank Cichocki, Jeffrey S Miller, Emil Lou, Himisha Beltran, Emmanuel S Antonarakis, Charles J Ryan, Justin H Hwang","doi":"10.1158/2767-9764.CRC-24-0501","DOIUrl":"10.1158/2767-9764.CRC-24-0501","url":null,"abstract":"<p><strong>Significance: </strong>DLL3-targeted therapies have recently shown robust clinical efficacy in aggressive neuroendocrine cancers, positioning them to fulfill a great unmet need in these settings. Here, we examine the clinical and biological correlates of DLL3 expression in both neuroendocrine and non-neuroendocrine cancers. Our findings may stimulate the development and application of DLL3-targeted therapies, as well as other precision therapies, in neuroendocrine cancers and beyond.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"318-326"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143054414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Urban Indian Organizations' Promotion of Cancer Services.","authors":"William O Carson, Alyssa Little, Angela Monetathchi, Jennifer Erdrich, Felina M Cordova-Marks","doi":"10.1158/2767-9764.CRC-24-0335","DOIUrl":"10.1158/2767-9764.CRC-24-0335","url":null,"abstract":"<p><strong>Significance: </strong>To the best of the knowledge of the authors, this is the first study to explore and measure cancer support services through public-facing channels. This study provides important data on how primary care facilities are engaging in public health promotion services in an online setting.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"369-374"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MYC and HSF1 Cooperate to Drive Sensitivity to Polo-like Kinase 1 Inhibitor Volasertib in High-grade Serous Ovarian Cancer.","authors":"Imade Williams, Matthew O'Malley, Haddie DeHart, Bobby Walker, Vrushabh Ulhaskumar, Pranav Jothirajah, Haimanti Ray, Lisa M Landrum, Joe R Delaney, Kenneth P Nephew, Richard L Carpenter","doi":"10.1158/2767-9764.CRC-24-0400","DOIUrl":"10.1158/2767-9764.CRC-24-0400","url":null,"abstract":"<p><strong>Significance: </strong>We show that HSF1 and MYC genes are co-amplified in more than 30% of HGSOC and demonstrate that HSF1 and MYC functionally cooperate to drive the growth of HGSOC cells. This work provides the foundation for HSF1 and MYC co-amplification as a biomarker for treatment efficacy of the polo-like kinase 1 inhibitor volasertib in HGSOC.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"253-266"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11799878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Loss of NF1 Accelerates Uveal and Intradermal Melanoma Tumorigenesis, and Oncogenic GNAQ Transforms Schwann Cells.","authors":"Anne Nathalie Longakit, Oscar Urtatiz, Amy Luty, Christina Zhang, Chloe Hess, Alyssa Yoo, Hannah Bourget, Catherine D Van Raamsdonk","doi":"10.1158/2767-9764.CRC-24-0386","DOIUrl":"10.1158/2767-9764.CRC-24-0386","url":null,"abstract":"<p><strong>Significance: </strong>These results indicate that NF1 loss in intradermal and uveal melanomas is a potentially significant finding. They emphasize the importance of neurofibromin in cAMP signaling. They show for the first time that oncogenic GNAQ can transform Schwann cells in mice. The Plp1-creERT transgene with tamoxifen given at 5 weeks may be a particularly good strategy for modeling cutaneous neurofibroma and plexiform neurofibroma.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"209-225"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers.","authors":"Andrew H Ko, Joseph Chao, Marcus S Noel, Veena Shankaran, Davendra Sohal, Mary Crow, Paul E Oberstein, Aaron J Scott, Autumn J McRee, Caio Max Sao Pedro Rocha Lima, Lawrence Fong, Bridget P Keenan, Maira Soto, Erin L Filbert, Frank J Hsu, Xiaodong Yang","doi":"10.1158/2767-9764.CRC-24-0513","DOIUrl":"10.1158/2767-9764.CRC-24-0513","url":null,"abstract":"<p><strong>Purpose: </strong>Neoadjuvant chemoradiation (NCRT) followed by surgical resection represents a standard approach for patients with locally advanced esophageal/gastroesophageal junction (GEJ) cancers. Sotigalimab is a high-affinity CD40 agonist antibody capable of inducing and expanding antitumor immune responses by activating dendritic cells, T and B lymphocytes, NK cells, and M1 macrophages. This study examined the safety and efficacy of combining sotigalimab with NCRT in patients with esophageal or GEJ cancers.</p><p><strong>Patients and methods: </strong>Patients with resectable (T1-3 Nx) adenocarcinoma or squamous cell carcinoma of the esophagus or GEJ were eligible. T1N0 and cervical tumors were excluded. Study treatment: weekly carboplatin/paclitaxel with concurrent radiation 5,040 cGy plus 3 to 4 doses of sotigalimab prior to Ivor Lewis esophagectomy. Primary efficacy endpoint was the pathologic complete response (path CR) rate.</p><p><strong>Results: </strong>Thirty-three patients were enrolled (adenocarcinoma 76%, squamous cell carcinoma 24%; and clinical stage III 67%). Ninety percent of patients received all planned doses of sotigalimab. The most common adverse events attributed to sotigalimab were nausea, fever/chills, fatigue, and cytokine release syndrome; most of these were grade 1 to 2. Grade ≥3 cytokine release syndrome was observed in 3 patients (9%). Twenty-five of the 29 efficacy-evaluable patients underwent an R0 resection (87.9%), with an overall path CR rate of 37.9% (11/29). Post-tumor samples demonstrated increased infiltration and activation of dendritic cells, monocytes, and cytotoxic T cells compared with baseline.</p><p><strong>Conclusions: </strong>Sotigalimab combined with NCRT for esophageal or GEJ cancers was generally well tolerated and achieved path CR rates that compare favorably with historical data and are promising for this treatment strategy. Clinical trial information: NCT03165994.</p><p><strong>Significance: </strong>The current study represents the first report to evaluate a CD40 agonist antibody in combination with concurrent chemoradiation in the neoadjuvant setting for patients with esophageal/GEJ cancers. This novel strategy was both safe and feasible, producing encouraging path CR rates that compare favorably with historical data. Our findings support the further evaluation of how immune-based therapies may be incorporated into perioperative treatment paradigms for upper gastrointestinal malignancies.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"349-357"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers.","authors":"Mariko Sasaki, Daiki Kato, Hiroshi Yoshida, Takafumi Shimizu, Hideaki Ogiwara","doi":"10.1158/2767-9764.CRC-24-0484","DOIUrl":"10.1158/2767-9764.CRC-24-0484","url":null,"abstract":"<p><strong>Significance: </strong>In this study, we clarified that the cBAF subcomplex is deficient in the SWI/SNF complex, resulting in dependency on the CBP/p300 paralog pair. Simultaneous inhibitors of the CBP/p300 paralog pair show promise for cBAF-deficient lung cancer, as well as rare cancers such as malignant rhabdoid tumors, epithelioid sarcomas, and synovial sarcomas.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"24-38"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11701801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}